BioCentury
ARTICLE | Company News

Elusys, Pfizer infectious disease deal

January 5, 2007 2:02 AM UTC

Elusys (Pine Brook, N.J.) and PFE partnered to develop infectious disease therapeutics using Elusys' Heteropolymer (HP) Antibody technology. The deal includes ETI-211 to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. ETI-211 is a preclinical heteropolymer antibody against complement receptor 1 ( CR1) receptor crosslinked with an antibody against S. aureus protein that is expected to enter the clinic in 2H08. ...